Posaconazole is a triazole antifungal drug marketed in the United States, the European Union, and in other countries by Schering-Plough under the trade name Noxafil. In Canada, posaconazole is marketed by Schering-Plough under the trade name Posanol.
Merck & Co says that a New Drug Application for a tablet formulation of the company’s antifungal Noxafil has been accepted for review by the US Food and Drug Administration.
Merck currently markets Noxafil (posaconazole) in liquid form for invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being “severely immunocompromised”. This covers patients who have received haematopoietic stem cell transplants and have graft-versus-host disease, or patients with cancers of the blood who are experiencing prolonged low white blood cell counts as a result of chemotherapy.
Specifically, Merck is seeking FDA approval of Noxafil tablets for once-daily administration, following a twice-a-day loading…
View original post 92 more words